Biomarin Pharmaceutical IncBMRN
ASignal's systematic analysis rates BMRN as Neutral.
Reflects the latest available analysis · analyzed Aug 23, 2026
The case on BMRN
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (19.9% YoY)
- Gross margin above 50%, indicating pricing power
- Debt-to-equity ratio of 0.66x, within moderate range
- Positive free cash flow with operating cash flow of $857M
- MACD above signal line, indicating bullish momentum
- Negative earnings growth (-81.3% YoY)
- Low return on equity (1.18%)
- High P/E ratio of 180.27x, suggesting overvaluation
- RSI at 66.12, approaching overbought territory
- No Reddit mentions, indicating low retail sentiment
See the full verdict on BMRN
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes BMRN
Most investors never get a second opinion, let alone several. ASignal runs BMRN past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.